This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
El e-Learning
Sánchez, L.; Munoz-Seca, BeatrizTechnical Note PN-415Service and Operations ManagementEl e-learning se está convirtiendo en un canal más para generar aprendizaje, tanto en el mundo educacional como en el empresarial. Aunque algunos autores consideran que su diseño debe tener en cuenta las características individuales del estilo de aprender del individuo, la mayoría de los programas de e-learning están desarrollados sin considerarlas. Este puede ser uno de los grandes orígenes de sus fracasos. La tecnología facilita un proceso, per...Starting at €8.20
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieTeaching Note HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Starting at €0.00
-
An Angel Investor with an Agenda (HBR Case Study)
Herzlinger, Regina E.; Munoz-Seca, BeatrizArticle HBS-R1103X-EEntrepreneurshipGloria Londono, the owner of a chain of innovative, holistic day care centers for the elderly in Spain, is offered 3 million euro by Victor Serna, a wealthy physician-investor. In exchange, Serna wants a 25% stake, a board seat, a vote on all strategic decisions, and the ability to liquidate his position in five years, either through a public offering or a sale. His terms are not negotiable; his objectives are not transparent. The money would ena...Starting at €8.20
-
An Angel Investor with an Agenda (Commentary for HBR Case Study)
Herzlinger, Regina E.; Munoz-Seca, BeatrizArticle HBS-R1103Z-EEntrepreneurshipGloria Londono, the owner of a chain of innovative, holistic day care centers for the elderly in Spain, is offered 3 million euro by Victor Serna, a wealthy physician-investor. In exchange, Serna wants a 25% stake, a board seat, a vote on all strategic decisions, and the ability to liquidate his position in five years, either through a public offering or a sale. His terms are not negotiable; his objectives are not transparent. The money would ena...Starting at €8.20
-
Caso de estudio: Un inversionista ngel con una agenda personal
Herzlinger, Regina E.; Munoz-Seca, BeatrizArticle HBS-R1103MEntrepreneurshipGloria Londoño, el dueño de una cadena de centros de día innovadoras e integrales para las personas mayores en España, se ofrece 3 millones de euros por Victor Serna, un acaudalado médico-inversor. A cambio, Serna quiere una participación del 25%, un puesto en la junta, un voto en todas las decisiones estratégicas, y la posibilidad de liquidar su posición en cinco años, ya sea a través de una oferta pública o una venta. Sus términos no son negoci...Starting at €8.20
-
An Angel Investor with an Agenda (HBR Case Study and Commentary)
Herzlinger, Regina E.; Munoz-Seca, BeatrizArticle HBS-R1103M-EEntrepreneurshipGloria Londono, the owner of a chain of innovative, holistic day care centers for the elderly in Spain, is offered 3 million euro by Victor Serna, a wealthy physician-investor. In exchange, Serna wants a 25% stake, a board seat, a vote on all strategic decisions, and the ability to liquidate his position in five years, either through a public offering or a sale. His terms are not negotiable; his objectives are not transparent. The money would ena...Starting at €8.20
-
Vitalia Franchise
Herzlinger, Regina E.; Munoz-Seca, BeatrizCase HBS-311035-ECathy Hoffmann has rapidly grown her novel facilities for day care therapy for elders with mild cognitive and physical problems. But she needs to decide whether to franchise or own the next expansion.Starting at €8.20
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Las nuevas tecnologías en el sector cultural
Herrero, Quionia; Marco, Elvira; Riverola, Josep; Munoz-Seca, BeatrizTechnical Note PN-455Knowledge and CommunicationLos museos, como instituciones dinámicas que desempeñan una función social, no son ajenos a las oportunidades que brindan las nuevas tecnologías. Éstas propician el acceso de un público más amplio a los contenidos e información de los museos y favorecen la relación entre la institución y algunos grupos sociales como los jóvenes o las personas con discapacidades. Los estudios sobre la manera en que afectan las nuevas tecnologías al público de los ...Starting at €8.20